help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rosenbaum, M.
Right arrow Articles by Leibel, R. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rosenbaum, M.
Right arrow Articles by Leibel, R. L.

Journal of Clinical Endocrinology & Metabolism, Vol 77, 352-355, Copyright © 1993 by Endocrine Society


ARTICLES

Lack of beta 3-adrenergic effect on lipolysis in human subcutaneous adipose tissue

M Rosenbaum, CC Malbon, J Hirsch and RL Leibel
Laboratory of Human Behavior and Metabolism, Rockefeller University, New York, New York 10021.

Human adipocytes are responsive to both alpha- (antilipolytic) and beta- (lipolytic) actions of catecholamine agonists. These effects are mediated by G proteins which interact with adenylcyclase beta 1- and beta 2-adrenoreceptor (AR) subtypes are identified in human adipose tissue. The existence of a third beta-adrenergic (beta 3) receptor has been recently proposed. The beta 3-AR has been reported to mediate catecholamine-induced cAMP accumulation and to be more responsive in this regard than either the beta 1- or the beta 2-AR. To examine the possibility that a beta 3-AR plays a significant role in the control of catecholamine-stimulated lipolysis in human adipose tissue, we used a sensitive in vitro measure of lipolysis. Abdominal and gluteal sc adipose tissue samples from 14 adults were incubated with isoproterenol, a nonspecific beta-AR agonist which activates adenylyl cyclase via all three beta-AR subtypes, in the presence of varying concentrations of a beta-AR antagonist, alprenolol, which blocks the beta 1- and beta 2-AR, but not the beta 3-AR. In tissue from both abdominal and gluteal sites, alprenolol (10(-3) M) completely abolished the lipolytic response to isoproterenol (10(-6) M). Alprenolol (10(-3) M) alone reduced basal lipolysis by 10.2 +/- 2.2% (SEM) in abdominal tissue (P < 0.01), and 7.1 +/- 2.7% in gluteal tissue (P < 0.05). In the presence of alprenolol (10(-3) M), isoproterenol (10(-6) M) had no demonstrable lipolytic effect. The probability of incorrect acceptance of the null hypothesis that isoproterenol had no effect on lipolysis in alprenolol-blocked tissue is P beta < 0.05 for both depots. As an additional control, pooled inguinal adipose tissue from adult male Sprague-Dawley rats was incubated with the same concentrations of alprenolol. Rat adipose tissue has been previously shown to express the beta 3-adrenoreceptor and lipolysis was increased in rat adipose tissue in the presence of alprenolol 10(-4) M and 10(-5) M. We conclude that beta 3-ARs, if present in human adipocyte plasma membranes, do not significantly affect rates of lipolysis.


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
J. Robidoux, N. Kumar, K. W. Daniel, F. Moukdar, M. Cyr, A. V. Medvedev, and S. Collins
Maximal beta3-Adrenergic Regulation of Lipolysis Involves Src and Epidermal Growth Factor Receptor-dependent ERK1/2 Activation
J. Biol. Chem., December 8, 2006; 281(49): 37794 - 37802.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Lafontan, C. Moro, C. Sengenes, J. Galitzky, F. Crampes, and M. Berlan
An Unsuspected Metabolic Role for Atrial Natriuretic Peptides: The Control of Lipolysis, Lipid Mobilization, and Systemic Nonesterified Fatty Acids Levels in Humans
Arterioscler. Thromb. Vasc. Biol., October 1, 2005; 25(10): 2032 - 2042.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
S. Guimaraes and D. Moura
Vascular Adrenoceptors: An Update
Pharmacol. Rev., June 1, 2001; 53(2): 319 - 356.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
C. C. Gerhardt, J. Gros, A. D. Strosberg, and T. Issad
Stimulation of the Extracellular Signal-Regulated Kinase 1/2 Pathway by Human Beta-3 Adrenergic Receptor: New Pharmacological Profile and Mechanism of Activation
Mol. Pharmacol., February 1, 1999; 55(2): 255 - 262.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
R. Büettner, A. Schäffler, H. Arndt, G. Rogler, J. Nusser, B. Zietz, I. Enger, S. Hügl, A. Cuk, J. Schölmerich, et al.
The Trp64Arg Polymorphism of the {beta} 3-Adrenergic Receptor Gene Is Not Associated with Obesity or Type 2 Diabetes Mellitus in a Large Population-Based Caucasian Cohort
J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 2892 - 2897.
[Abstract] [Full Text]


Home page
J. Cell Sci.Home page
V Zilberfarb, F Pietri-Rouxel, R Jockers, S Krief, C Delouis, T Issad, and A. Strosberg
Human immortalized brown adipocytes express functional beta3-adrenoceptor coupled to lipolysis
J. Cell Sci., January 4, 1997; 110(7): 801 - 807.
[Abstract] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
P. Barbe, V. Stich, J. Galitzky, M. Kunesova, V. Hainer, M. Lafontan, and M. Berlan
In Vivo Increase in {beta}-Adrenergic Lipolytic Response in Subcutaneous Adipose Tissue of Obese Subjects Submitted to a Hypocaloric Diet
J. Clin. Endocrinol. Metab., January 1, 1997; 82(1): 63 - 69.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1993 by The Endocrine Society